Anzeige
Meldung des Tages: Antimon wieder im Fokus: ATMY erreicht Allzeithoch – Verteidigungsnachfrage treibt den Markt

Artivion News

Aktie
WKN:  900006 ISIN:  US2289031005 US-Symbol:  AORT Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
37,76 $
+0,60 $
+1,61%
32,223 € 24.04.26
Depot/Watchlist
Marktkapitalisierung *
1,62 Mrd. €
Streubesitz
4,41%
KGV
73,08
Index-Zuordnung
-

Artivion News

23.04.26 - PR Newswire
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results PR Newswire
07.04.26 - PR Newswire
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System PR Newswire
03.03.26 - PR Newswire
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference PR Newswire
12.02.26 - PR Newswire
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire
02.02.26 - PR Newswire
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting PR ...
29.01.26 - PR Newswire
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results PR Newswire
06.11.25 - PR Newswire
Artivion Reports Third Quarter 2025 Financial Results
Artivion Reports Third Quarter 2025 Financial Results PR Newswire
06.11.25 - PR Newswire
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial PR Newswire
29.10.25 - PR Newswire
Artivion to Participate in the Stifel 2025 Healthcare Conference
Artivion to Participate in the Stifel 2025 Healthcare Conference PR Newswire
23.10.25 - PR Newswire
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results PR Newswire
13.10.25 - PR Newswire
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
Artivion Announces Presentation of Late-​Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-​Thoracic Surgery (EACTS) ...
05.09.25 - PR Newswire
Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference PR Newswire
07.08.25 - PR Newswire
Artivion Reports Second Quarter 2025 Financial Results
Artivion Reports Second Quarter 2025 Financial Results PR Newswire
30.07.25 - PR Newswire
Artivion to Participate in Upcoming Investor Conferences
Artivion to Participate in Upcoming Investor Conferences PR Newswire
24.07.25 - PR Newswire
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results PR Newswire
03.06.25 - PR Newswire
Artivion to Participate in Upcoming Investor Conferences
Artivion to Participate in Upcoming Investor Conferences PR Newswire
28.05.25 - PR Newswire
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock PR Newswire
14.05.25 - PR Newswire
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock PR Newswire
05.05.25 - PR Newswire
Artivion Reports First Quarter 2025 Financial Results
Artivion Reports First Quarter 2025 Financial Results PR Newswire
05.05.25 - PR Newswire
Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting
Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting PR Newswire

Newssuche

Videos

newspaper
20.04.26 +3,18%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »